Latest From Incyte Corp.
The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.
While Pfizer’s JAK3 inhibitor is in Phase II/III for alopecia areata, Concert thinks its deuterium-modified ruxolitinib may get to market sooner. However, the breadth of Incyte’s ruxolinitib patent protection is unclear.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Incyte Pharmaceuticals Inc.
- Incyte Genomics Inc.
- North America
- Parent & Subsidiaries
- Incyte Corp.
- Senior Management
Hervé A Hoppenot, MD, Pres. & CEO
David W Gryska, EVP, CFO
Dashyant Dhanak , PhD, EVP, CSO
Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
Steven H Stein, MD, EVP, CMO
- Contact Info
Phone: (302) 498-6700
1801 Augustine Cut-Off
Wilmington, DE 19803
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.